BridgeBio Pharma Other Operating Income or Expenses 2018-2024 | BBIO
BridgeBio Pharma annual/quarterly other operating income or expenses history and growth rate from 2018 to 2024. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
- BridgeBio Pharma other operating income or expenses for the quarter ending September 30, 2024 were $-0.005B, a 1598.9% increase year-over-year.
- BridgeBio Pharma other operating income or expenses for the twelve months ending September 30, 2024 were $-0.012B, a 21.51% decline year-over-year.
- BridgeBio Pharma annual other operating income or expenses for 2023 were $-0.008B, a 81.89% decline from 2022.
- BridgeBio Pharma annual other operating income or expenses for 2022 were $-0.044B, a INF% decline from 2021.
- BridgeBio Pharma annual other operating income or expenses for 2021 were $0B, a NAN% decline from 2020.
BridgeBio Pharma Annual Other Operating Income or Expenses
(Millions of US $) |
| 2023 |
$-8 |
| 2022 |
$-44 |
| 2021 |
$ |
| 2020 |
$ |
| 2019 |
$ |
| 2018 |
$ |
| 2017 |
$ |
BridgeBio Pharma Quarterly Other Operating Income or Expenses
(Millions of US $) |
| 2024-09-30 |
$-5 |
| 2024-06-30 |
$-3 |
| 2024-03-31 |
$-3 |
| 2023-12-31 |
$-1 |
| 2023-09-30 |
$-0 |
| 2023-06-30 |
$-4 |
| 2023-03-31 |
$-3 |
| 2022-12-31 |
$-8 |
| 2022-09-30 |
$-5 |
| 2022-06-30 |
$-8 |
| 2022-03-31 |
$-23 |
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.773B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
